Obstructive lung diseases, including asthma and COPD, are characterized by air-flow
limitation. Bronchodilator therapy can often decrease symptoms of air-flow obstruction by …

Bronchodilators remain the cornerstone of the treatment of airway disorders such as asthma
and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest …

Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Introduction: Inhaled bronchodilators are the mainstay of the current management of COPD
at all stages of the disease, and are critical in the symptomatic management of asthma …

Novel long-acting β 2-agonists (eg indacaterol, vilanterol, olodaterol and carmoterol) and
muscarinic antagonists (eg tiotropium, aclidinium, glycopyrronium and umeclidinium …

Despite current guidelines and the range of available treatments, over a half of patients with
asthma continue to suffer from poor symptomatic control and remain at risk of future …

Bronchodilators remain central to the symptomatic management of chronic obstructive
pulmonary disease and asthma, and, for this reason and also because the patent protection …

β2-Agonists are effective bronchodilators due primarily to their ability to relax airway smooth
muscle (ASM). They exert their effects via their binding to the active site of β2-adrenoceptors …

Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists,
are the mainstay of pharmacotherapy in chronic obstructive pulmonary disease (COPD). The …

Introduction Strong scientific evidence and large experience support the use of β2-agonists
for the symptomatic alleviation of COPD. Therefore, there is considerable effort in …